If you have been reading about insulin-like growth factor 1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
A functional graphene integrated circuit was demonstrated—a complementary inverter consisting of one p- and one n-type transistor. However, this inverter suffered from low voltage gain. Typically, the amplitude of the output signal is about 40 times less than that of the input signal. Moreover, none of these circuits operated at frequencies higher than 25 kHz. In the same year, tight-binding numerical simulations demonstrated that the band-gap induced in graphene bilayer field effect transistors is not sufficiently large for high-performance transistors for digital applications, but can be sufficient for ultra-low voltage applications, when exploiting a tunnel-FET architecture. In February 2010, researchers announced graphene transistors with an on-off rate of 100 gigahertz, far exceeding prior rates, and exceeding the speed of silicon transistors with an equal gate length. The 240 nm devices were made with conventional silicon-manufacturing equipment. According to a January 2010 report, graphene was epitaxially grown on SiC in a quantity and with quality suitable for mass production of integrated circuits. At high temperatures, the quantum Hall effect could be measured. IBM built 'processors' using 100 GHz transistors on 2-inch (51 mm) graphene sheets. In June 2011, IBM researchers announced the first graphene-based wafer-scale integrated circuit, a broadband radio mixer. The circuit handled frequencies up to 10 GHz. Its performance was unaffected by temperatures up to 127 °C. In November researchers used 3D printing (additive manufacturing) to fabricate devices.
Soon after settling into his new home on Riverside Drive, Adorno met with Lazarsfeld in Newark, New Jersey, to discuss the Project's plans for investigating the impact of broadcast music. Although he was expected to embed the Project's research within a wider theoretical context, it soon became apparent that the Project was primarily concerned with data collection to be used by administrators for establishing whether groups of listeners could be targeted by broadcasts specifically aimed at them. Expected to make use of devices with which listeners could press a button to indicate whether they liked or disliked a particular piece of music, Adorno bristled with distaste and astonishment: "I reflected that culture was simply the condition that precluded a mentality that tried to measure it." Thus, Adorno suggested using individual interviews to determine listener reactions and, only three months after meeting Lazarsfeld, completed a 160-page memorandum on the Project's topic, "Music in Radio." Adorno was primarily interested in how musical material was affected by its distribution through the medium of radio and thought it imperative to understand how music was affected by its becoming part of daily life.
doi:10.1126/scitranslmed.aaf1059. PMC 5505565. PMID 27225182. Park, J; Wetzel, I; Marriott, I; Dréau, D; D'Avanzo, C; Kim, D-Y; Tanzi, RE; Cho, H (2018). "Neuron-Glia Interactions Recapitulated in a 3D Organotypic Human Alzheimer's Disease Brain Model". Nature Neuroscience. 21 (7): 941–951. doi:10.1038/s41593-018-0175-4. PMC 6800152. PMID 29950669. Eimer, WA; Kumar, D; Kumar, N; Breakefield, XO; Tanzi, RE; Moir, RD (2018). "Alzheimer's Disease-Associated b-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection". Neuron. 99 (1): 1–9. doi:10.1016/j.neuron.2018.06.030. PMC 6075814. PMID 30001512.
== Applications == The shikimate pathway is a target for herbicides and other non-toxic drugs because the shikimate pathway is not present in humans. Glyphosate, a commonly used herbicide, is an inhibitor of 5-enolpyruvylshikimate 3-phosphate synthase or EPSP synthase, an enzyme in the shikimate pathway. The problem is that this herbicide has been utilized for about 20 years and now some plants have now emerged that are glyphosate-resistant. This has relevance to research on shikimate dehydrogenase because it is important to maintain diversity in the enzyme blocking process in the shikimate pathway and with more research shikimate dehydrogenase could be the next enzyme to be inhibited in the shikimate pathway. In order to design new inhibitors the structures for all the enzymes in the pathway have needed to be elucidated. The presence of two forms of the enzyme complicate the design of potential drugs because one could compensate for the inhibition of the other. Also there the TIGR data base shows that there are 14 species of bacteria with the two forms of shikimate dehydrogenase. This is a problem for drug makers because there are two enzymes that a potential drug would need to inhibit at the same time.
Sources: en.wikipedia.org
== Challenges == The space environment is expected to be beneficial for production of a variety of products assuming the obstacles to it can be overcome. The most significant cost is overcoming the energy hurdle for boosting materials into orbit. Once this barrier is significantly reduced in cost per kilogram, the entry price for space manufacturing can make it much more attractive to entrepreneurs. After the heavy capitalization costs of assembling the mining and manufacturing facilities are paid, the production will need to be economically profitable in order to become self-sustaining and beneficial to society. The economic requirements of space manufacturing imply a need to collect the requisite raw materials at a minimum energy cost. The cost of space transport is directly related to the delta-v, or change in velocity required to move from the mining sites to the manufacturing plants. Bringing material to Earth orbit from bodies such as Near-Earth asteroids, Phobos, Deimos or the lunar surface requires far less delta-v than launching from Earth itself, despite the greater distances involved. This makes these places economically attractive as sources of raw materials.
Although the party's ideology has shifted throughout its existence, it has consistently presented itself through a Christian democratic and politically Catholic profile. It was seen to occupy the political centre, although the party is considered to have shifted towards the right of centre in early 1930s under the leadership of Ludwig Kaas. The Oxford Handbook of the Weimar Republic argues that while "Until recently, historians considered Kaas to have been an... ominous indication of the Centre’s shift to the right", the party's position was "more nuanced", as it continued to accept the legitimacy of the Weimar Republic and its constitution, and Kaas strove to reconcile both the left-leaning and right-leaning wings of the party. The party adopted a new program in 2008 in which it stated rejection for the traditional left and right divide of politics and called for a "value-oriented" platform guided by the principles of Christianity and Basic Law for the Federal Republic of Germany. The party supports the traditional family unit and is generally opposed to abortion. It has given support to right to life movements in Germany. During the Weimar era, the Centre Party was socially and economically heterogenous and included groups of various political views and interests, including republicans and monarchists. It represented the entire "political microcosm of Weimar Catholic society".
=== Genome structure === The S. haemolyticus strain JCSC1435 genome contains a 2,685,015 bp chromosome and three plasmids of 2,300 bp, 2,366 bp, and 8,180 bp. The chromosome is comparable in size to those of S. aureus and S. epidermidis and contains a similar G+C content. In addition, a large proportion of the open reading frames (ORFs) are conserved across all three species. On average, orthologous ORFs are 78% identical. However, S. haemolyticus does have unique chromosome regions distributed near oriC (the origin of chromosomal DNA replication), and these regions are collectively referred to as the “oriC environ”. As noted, some S. haemolyticus ORFs differ from S. aureus and S. epidermidis. Some of these ORFs encode gene products with known biological features, such as the regulation of RNA synthesis, the transport of ribose and ribitol, and the essential components of nucleic acid and cell wall teichoic acid biosynthesis. Other unique ORFs likely encode products involved with bacterial pathogenesis and at least three of these ORFs show homology to staphylococcal hemolysins. The S. haemolyticus genome also contains many insertion sequences (ISs). These IS elements may promote frequent genomic rearrangements which accelerate the diversification of the species. Theoretically, these adaptations might help S. haemolyticus overcome the adverse effects of chemical exposure (i.e. the use of antibiotics). The table below contains a list of genes known to be associated with S. haemolyticus antibiotic resistance.
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.